The Safety and Effectiveness of PMPA Prodrug in HIV-Infected Patients
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To evaluate the safety of single and multiple doses (28 daily doses) of
9-[2-(R)-[[bis[[(isopropoxycarbonyl)- oxy]methoxy]phosphinoyl]methoxy]propyl]adenine fumarate
(PMPA) prodrug administered orally to HIV-infected patients. To determine the
pharmacokinetics of single and multiple doses of PMPA prodrug when administered orally to
HIV-infected patients. To evaluate the anti-HIV activity of PMPA prodrug, as demonstrated by
increases in CD4 cell counts and decreases in HIV RNA, when administered orally as a single
dose and daily for 4 weeks to HIV-infected patients with CD4 cell counts of 200 or more
cells/mm3.